Efficacy of S-1 (Taiho Pharmaceutical Co, Tokyo, Japan) used in combination with docetaxel (S-1DDOC) for breast cancer was evaluated. After 4 cycles of S-1DDOC, patients with a complete response (CR) underwent surgery, and those with partial response underwent 4 more cycles. Patients with stable disease or progressive disease received epirubicin and cyclophosphamide or trastuzumab and paclitaxel. The pathological CR rate was 29 patients [34.9%], and 8 patients [19.5%] for patients with luminal type breast cancer. S-1DDOC was expected to be an effective chemotherapy for luminal type breast cancer. Background: To improve the pathological complete response (pCR) rate, we devised new neoadjuvant chemotherapy. Efficacy and safety of the oral fluoropyrimidine derivative S-1 (Taiho Pharmaceutical Co, Tokyo, Japan) combined with low-dose docetaxel (S-1þDOC) were evaluated. Patients and Methods: Patients were treated with docetaxel (40 mg/m 2 intravenously on day 1) and S-1 (40 mg/m 2 orally twice per day on days 1-14) every 3 weeks for 4
Introduction
Neoadjuvant chemotherapy (NAC) has become a standard treatment for breast cancer. The effectiveness of NAC has been documented as follows. Breast cancer patients treated with NAC achieved similar overall survival and disease-free survival rates compared with the patients treated with adjuvant chemotherapy. pCR rate in breast cancer patients. 2, [6] [7] [8] In addition, sensitivity to NAC can be determined within a short period of time. Anthracycline-based followed by taxane regimens did not yield satisfactory pCR rates especially for patients with luminal type breast canceer. 8 Anthracycline can cause severe bone marrow suppression and cardiotoxicity. S-1 (Taiho Pharmaceutical Co, Tokyo, Japan) is an oral fluoropyrimidine derivative composed of tegafur, gimeracil, and potassium oxonate. The S-1 monotherapy response rate (RR) among advanced breast cancer patients was 41.7% 9 and that for breast cancer after resistance to anthracycline and taxane was 33.3%. 10 S-1 is thus expected to play a part in the new strategies for breast cancer therapy. S-1 and docetaxel (DOC) combination therapy (S-1þDOC) was reported to have a synergistic antitumor effect in a breast cancer xenograft study, which was suggested to be partly via a significant downregulation of the activity of dihydropyrimidine dehydrogenase, the rate-limiting enzyme in the catabolism of fluorouracil (5-FU). 11, 12 S-1þDOC has been established for gastric cancer. [13] [14] [15] With the combination of S-1 with low-dose DOC adopted in this study, we expected those synergic effects.
In general, NAC required 24 weeks and prolonged the time to surgery. Therefore, a concern for losing the chance for resection exists. This new combination regimen is expected to achieve high pCR rates in a short period of time. The present study was designed to evaluate the response of S-1þDOC after 4 cycles of administration according to the Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST) criteria, and the regimen was switched to EC (epirubicin and cyclophosphamide), or HT (trastuzumab and paclitaxel) according to HER2 status if the response was stable disease (SD) or progressive disease (PD).
Patients and Methods

Study Design and Patient Selection
Eligible patients were 20 to 75 years of age, with histologically confirmed invasive, but noninflammatory primary breast cancer with stage II (tumor size >2 cm) to IIIB disease, and were enrolled in this study if they satisfied the following eligible criteria. They were required to have an Eastern Cooperative Oncology Group performance status of 0 or 1, and were neither pregnant nor nursing. All patients were required to have adequate bone marrow function (absolute neutrophil count > 2.0 Â 10 3 , platelet count 100 Â 10 3 , and hemoglobin level > 9 g/dL) and hepatic and renal functions confirmed in a prestudy examination (ie, bilirubin level < 1.5 times the upper normal limit [UNL], aspartate aminotransferase and or alanine aminotransferase <3 times the UNL, and creatinine clearance !60 mL/min). Patients with a history of other cancer within the previous 5 years, heart failure, diabetes mellitus needing continuous insulin therapy, active infection, or mental disease were excluded.
The institutional review board of the Tokushima University Hospital authorized the study. Before entry into the study, each patient was informed about the investigational nature of the study, and written informed consent that was approved by the institutional review board was obtained.
Histologic confirmation of the tumor was performed using core needle biopsy before NAC at the time of breast cancer diagnosis. Estrogen receptor (ER), progesterone receptor (PgR), and HER2 was assessed using immunohistochemistry (IHC). The hormone receptor status was considered positive if >10% of the tumor cells were positively stained for ER and/or PgR. HER2 status was determined using IHC and confirmed with either fluorescent in situ hybridization (FISH) if the IHC result was equivocal (ie, 2þ). Fine-needle aspiration of lymph nodes clinically suspected to be diseased was performed. A FISH amplification rate of >2.0 was considered positive. Figure 1 ). The dose of S-1 was reduced by 20 mg/d if Grade !3 toxicity was observed.
Treatment Schedule
Patients did not receive granulocyte colony-stimulating factor (G-CSF) unless a neutropenic fever occurred. If a patient experienced severe toxicity, a thorough supportive therapy was used in addition to maintain compliance with the S-1 regimen; G-CSF was administered for neutropenic fever, metoclopramide for nausea, lorazepam for anticipatory nausea, alprazolam for depression, and polaprezinc for dysgeusia.
Response Evaluation and Assessment of Adverse Events
Radiographic evaluations to determine the tumor response were performed after 4 cycles and 8 cycles using computed tomography (CT) scan, magnetic resonance imaging (MRI), mammography, and ultrasonography. According to the RECIST guidelines, CR was defined by the disappearance of all targeted lesions. pCR was defined as the disappearance of the invasive primary tumor and axillary lymph node metastasis determined pathologically (ypT0N0). Quasi-pCR (QpCR) was defined as the absence of invasive tumor or only focal residual tumor cells (ypTisN0). 16 PR was defined as a !30% decrease in the sum of the diameters of the target lesions, PD was defined as an increase of !20% in the sum of the diameters of the target lesions. Patients who exhibited neither sufficient shrinkage to qualify for a PR or nor a sufficient increase to qualify for PD were considered to have SD.
In accord with the Common Terminology Criteria for Adverse Events version 3.0, toxicity was evaluated after each cycle of chemotherapy.
Surgery and Adjuvant Therapy
Each patient proceeded to surgery after completion of each study schedule. The decision to proceed to mastectomy or BCS was at the Clinical Breast Cancer February 2019 -11 discretion of the surgeon and the patient. All patients with axillary lymph node metastasis before chemotherapy underwent axillary lymph node dissection (ALND). The patients who were clinically node-negative underwent a sentinel lymph node (SLN) biopsy. Clinically N0 patients who showed metastasis in an SLN in pathology were recommended for ALND. All patients who underwent BCS received whole-breast irradiation. Postmastectomy radiotherapy was used in patients with clinical stage III or clinical tumor size !5 cm at diagnosis, and in those with pathologic involvement of !4 axillary lymph nodes. 
Assessment End Point
The primary end point was the rate of pCR defined as no microscopic residual viable invasive tumor cells in all resected breast specimens. The secondary end points were the feasibility, RR, BCS rate, and compliance with oral S-1. 
S-1DDocetaxel As Neoadjuvant Chemotherapy For Breast Cancer Statistical Analysis
This was a phase II trial with a single-stage design on the basis of binominal distribution, with a 1-sided threshold efficacy rate of 30.0%, which was the lowest pCR rate, an expected pCR rate of 50.0%. When defining an a error of .05 and b error of .10, a total of 55 patients were required to account for dropout cases. Patient characteristics and toxicity are presented as percentages.
Results
Patient Characteristics
From May 2009 to December 2013, 94 patients were enrolled in this study. The full analysis population consisted of 83 patients (Figure 2) .
The median age was 53 years (range, 24-75 years), and 38.6% of the patients were premenopausal. Response rate was recognized in 92.3% of luminal HER2, 84.6% of HER2, 87.5% of TN, and 75.6% in luminal type patients (Table 3) . 16 Clinical CR (cCR) was seen in 5 patients after 4 courses of the regimen. Shrinkage of the tumor was recognized after 2 courses of the regimen in many patients. Pathological CR (pCR) was recognized in 53.8% of luminal HER2, 46.1% of HER2, 50.0% in TN, and 19.5% in luminal type patients (Table 3) . BCS was possible in 65 cases (78.3%). Twenty-one patients showed SD and PD with this regimen, 12 patients with HER2
À received 4 courses of EC and 9 patients with HER2 þ breast cancer received 4 courses of HT. Two pCRs and 9
pathological PRs (pPRs) were recognized in those 12 patients. Nine patients were treated with sequential HT. pCR and QpCR was recognized in 4 patients, and 4 pPRs in 9 patients treated with sequential HT (Table 4) . 16 Therefore, the overall RR in this study was 80.7%, and the pCR rate was 34.9%. These RRs and pCR rates were superior compared with the previous study.
Safety
The number of patients who were able to continue taking >80% of their required S-1 dose was 68 (81.9%). The adverse events are summarized in 
Discussion
Docetaxel and 5-FU have been shown to be synergistic in vivo and in vitro, which constitutes the rationale for combining S-1 and DOC. 17 A phase I study was carried out to determine the maximum tolerated dose and the recommended dose of DOC with a fixed dose of S-1. We carried out the phase I study in Japanese gastric cancer patients. 13 The pCR rate was 34.9% in this population. In other NAC studies, the pCR rates ware 14% to 35.4%. operable patients receiving neoadjuvant anthracyclineetaxane-based chemotherapy using data from 7 randomized control trials (RCTs), in which T status was almost identical to ours, and showed that of 6377 patients, 1450 achieved a pCR (22.7%), and for 1849 patients of the luminal type 145 achieved a pCR (7.8%. 20 As a result, our pCR rates were higher compared with theirs although it is difficult to compare simply because our study had a small sample size enrolled, and it was a phase II trial. However, we believe that our regimen is expected to be effective NAC in terms of achieving good pCR. Anthracycline and taxane-based therapy, which is a standard regimen, is known to have low efficacy against breast cancer of the luminal type. Moreover, this regimen with S-1 and low-dose DOC showed patients to achieve a cCR in a very short time period, compared with the previous sequential regimens. [3] [4] [5] [6] [7] [8] [18] [19] [20] courses of EC and 9 patients who were HER2 þ received 4 courses of HT. Two pCRs and 9 pPRs were recognized in those 12 patients. Nine patients were treated with sequential HT. pCR and QpCR was recognized in 4 patients; 4 pPRs in 9 patients treated with sequential HT (Table 4 ). Only 3 of 83 patients could not achieve efficacy in this study (1 patient with PD and 2 with SD). Eighty of 83 patients (96.4%) obtained clinical benefit from this study.
Response rates were superior compared with to those in the previous study. 20 Efficacy of S-1 against luminal type breast cancer has attracted attention recently. The pCR rate was 19.5% in the patients with the luminal type who were treated with this regimen. Although Ki-67 Table 4 
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evaluation was not performed in all luminal type patients in this study, pCR did not depend on the Ki-67 value in calculations using data from several patients who had Ki-67 evaluated in this study. Of 8 pCR cases of luminal type, 3 (32.5%) cases were luminal A, and 5 (62.5%) were luminal B. This result would realize the effective chemotherapy even in luminal A type breast cancer, in which NAC was not performed, with remarkable efficacy. 19 The SELECT BC (SELection of Effective ChemoTherapy for Breast Cancer) trial showed that S-1 is not inferior to taxane as a first-line treatment for metastatic breast cancer. In the subgroup analyses, S-1 was effective against hormone receptor-positive tumors. 21 Thus, oral Se1-based therapy compares favorably with the standard regimen, especially for the luminal type cancer. Two patients with TN type tumor showed pathological PD. One of them was spindle-cell carcinoma. The other patient achieved a pPR after the sequential EC treatment. Among the 5 patients who underwent surgery after 4 cycles of S-1þDOC, pCR was achieved in 3 patients (2 TN, 1 HER2 type), pPR was achieved in 1 patient (HER2 type), and pathological SD was observed in 1 patient (luminal type). In TN or HER2 type, 24 patients underwent 8 cycles of S-1þDOC. Twelve of them achieved pCR. Some research groups have indicated that the pCR after NAC can be considered a prognostic factor in advanced TN type and HER2 type cancer. 3, 4, 20 One patient with luminal type cancer achieved pathological SD according to resected specimen examination. In our study, the determination of cCR was on the basis of MRI, CT scan, mammography, and ultrasonography, but several studies showed that MRI measurement was inaccurate for luminal type cancer. [22] [23] [24] The determination of cCRs should be interpreted with caution according to the subtype. Moon et al described their use of S-1þDOC after AC (doxorubicin with cyclophosphamide) as NAC. 25 In that study, the patients received AC every 3 weeks cycles. The pCR rate was 22.5% and the clinical RR was 67.4%; 85.4% of the patients completed 8 cycles of therapy. There was a single treatment-related mortality from severe neutropenia.
Gastrointestinal discomfort led to a dose reduction of S-1 in 45.8% of the patients. 25 In our present study, DOC (40 mg/m 2 I.V. on day 1) and S-1 (40 mg/m 2 orally B.I.D. on days [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] were used in accord with a phase I study of Japanese patients with recurrent gastric cancer. 14 Our results are better when they are recalculated without HER2 cases (pCR rate of 28.0% and RR rate of 77.2%).
Because of the S-1 is an oral medicine that is taken by the patient by themselves at home, it is particularly important that the patients maintain compliance with the drug regimen. There are few reports about compliance regarding oral medications for breast cancer. However, this regimen is one of the standard treatment regimens for gastric cancer treatment in Japan. In the treatment of gastric cancer, it was reported that the second-generation histamine H2 receptor antagonist lafutidine might be useful not only for preventing gastrointestinal toxicities during adjuvant chemotherapy, but also for improving compliance with a regimen of oral 5-FU anticancer drugs. 26 Supportive therapy was provided for almost all patients, who revealed adverse events in this study. Sixty-eight patients (81.9%) took S-1 at more than 80% of the required dose. Some patients stopped taking S-1 before the 14-day point was reached, because of Grade 1/2 gastrointestinal symptoms or fatigue. Although S-1 treatment can provide a superior quality of life, 21 its use requires close supervision because it is an oral medicine. It will be important to identify predictive factors for S-1 effects and adverse events, and to provide regular examinations as a back-up. There was no mortality in our study.
Limitations
Because this study was phase II, the patients' long-term outcome was not described. von Minckwitz et al also addressed the Further studies are needed. The patients who received surgery after 4 cycles S-1þDOC should be verified. The sample size was small and the judgement of cCR should be reconsidered. There is a potential that NAC treatment time can be shortened. These patients need adequate follow-up.
Conclusion
The S-1þDOC regimen in this present study could be well tolerated and a new candidate NAC in operable breast cancer patients. It is also expected to be effective even in patients with luminal type disease. However, further RCTs will be needed to ascertain whether pCR can contribute to favorable outcomes.
Clinical Practice Points
To improve the pCR rate, we devised a new NAC treatment. Efficacy and safety of the oral fluoropyrimidine derivative S-1 combined with low-dose DOC were evaluated. Patients were treated with S-1þDOC for 4 cycles. In accord with the RECIST criteria, the patients who showed a CR underwent surgery, and those who achieved a PR underwent 4 more cycles of S-1þDOC. Patients with SD or PD received EC or HT according to their HER2 status. The primary end point was the pCR rate. Ninety-four patients entered the study. After 4 cycles of S-1þDOC, CR was noted in 5 patients, PR in 57, SD in 18, and PD in 3. Among the 83 assessable patients, the pCR rate was 34.9%, and the RR was 80.7%. The pCR rates were 19.5% for patients with the luminal type breast cancer. Patients who received S-1þDOC showed a previous response to a previous protocol with anthracycline with cyclophosphamide followed by taxane treatment. Our results suggest that S-1þDOC was expected to be an effective chemotherapy for luminal-type breast cancer.
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